flezurafenib   Click here for help

GtoPdb Ligand ID: 13233

Synonyms: compound A-1 [WO2022023450]
Compound class: Synthetic organic
Comment: The chemical structure for flezurafenib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor with proposed antineoplastic action. It is one of the Raf inhibitors claimed in patent WO2022023450A1 [1]. Investigation of Jazz Pharmaceuticals' pipeline suggests that flezurafenib may be their oral pan-Raf inhibitor clinical lead JZP815. This lead is being explored for efficacy against solid tumours and haematologic malignancies harbouring oncogenic mutations that activate the RAS-RAF-MAPK pathway. We will update this entry when the structure for flezurafenib or JZP815 is publicly disclosed.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 84.31
Molecular weight 456.47
XLogP 0.92
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=CC=C1C2=CNC(=N2)[C@@H]3CC4=CC(=CC=C4OC3)OC5=CC=NC6=C5CCC(=O)N6)F
Isomeric SMILES FC1=CC=C(C=C1)C=2N=C(NC2)[C@H]3COC4=C(C3)C=C(C=C4)OC5=C6CCC(NC6=NC=C5)=O
InChI InChI=1S/C26H21FN4O3/c27-18-3-1-15(2-4-18)21-13-29-25(30-21)17-11-16-12-19(5-7-22(16)33-14-17)34-23-9-10-28-26-20(23)6-8-24(32)31-26/h1-5,7,9-10,12-13,17H,6,8,11,14H2,(H,29,30)(H,28,31,32)/t17-/m1/s1
InChI Key TWJSMWXWCWQPRO-QGZVFWFLSA-N
No information available.
Summary of Clinical Use Click here for help
JZP815 is a clinical trial candidate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05557045 A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 Phase 1 Interventional Jazz Pharmaceuticals